Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 5, 2026

Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin

View original at seekingalpha.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin Earnings Call Insights: Samsara (IOT) Q1 fiscal 2027 MANAGEMENT VIEW * "Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth" (CEO Sanjit Biswas), including: "We ended Q1 with ne…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Large enterprise deal cycles can take multiple quarters

    60% confidence
  • Samsara uses coding bots and agents internally and is automating workflows

    60% confidence
  • Samsara is experimenting with different pricing models for new intelligence products

    60% confidence
  • Large customers see an opportunity to bring workflows together on one platform

    60% confidence
  • Q2 non-GAAP EPS expected to be between $0.15 and $0.16

    60% confidence
  • Samsara has only been offering Connected Asset Maintenance for a few quarters now

    60% confidence
  • FY2027 non-GAAP operating margin expected to be 20%

    60% confidence
  • AI/cloud cost pressure is being mitigated via COGS-related optimizations and OPEX reallocation

    60% confidence
  • Samsara ended Q1 with nearly $2 billion in ARR, growing 30% year-over-year

    60% confidence
  • Q1 revenue was $479 million

    60% confidence
  • Samsara expects to be GAAP profitable for Q2

    60% confidence
  • Q1 strength was driven by strength in emerging products

    60% confidence
  • At some point Samsara may offer a consumption-based pricing model for agents

    60% confidence
  • Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth

    60% confidence
  • Ground Intelligence is priced on a per mile basis

    60% confidence
  • Samsara raised the full-year non-GAAP operating margin target from 19% to 20%

    60% confidence
  • 96% of $100,000-plus ARR customers subscribe to two or more products

    60% confidence
  • The full-year guide raise is almost double the amount of the Q1 beat

    60% confidence
  • Samsara is emphasizing LTM (last 12 months) figures to reduce perceived volatility from large deal timing

    60% confidence
  • GAAP EPS would still be positive excluding the Motive arbitration award

    60% confidence
  • Q2 non-GAAP operating margin expected to be 18%

    60% confidence
  • Samsara's guidance philosophy remains the same and is de-risked for potential downside scenarios

    60% confidence
  • DRAM and NAND supply chain conditions are a little bit tighter

    60% confidence
  • Connected Asset Maintenance helps customers shift from time-based and mileage-based maintenance schedules to a data-driven approach

    60% confidence
  • FY2027 non-GAAP EPS expected to be between $0.70 and $0.72

    60% confidence
  • Samsara also expects to be GAAP profitable for full year FY '27

    60% confidence
  • Emerging products contributed more than 20% of net new ACV for the second consecutive quarter

    60% confidence
  • Samsara is spending more money on AI and cloud, pressuring gross margin

    60% confidence
  • Emerging products were more than 20% of net new ACV in Q1 versus 23% of net new ACV in Q4 FY2026

    60% confidence
  • Samsara has confidence it will be able to find the supply it needs

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com